TG Therapeutics, Inc. $TGTX Stake Increased by Sei Investments Co.

Sei Investments Co. lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 141.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 176,702 shares of the biopharmaceutical company’s stock after buying an additional 103,634 shares during the period. Sei Investments Co.’s holdings in TG Therapeutics were worth $5,870,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Maryland State Retirement & Pension System grew its stake in TG Therapeutics by 2.0% during the 4th quarter. Maryland State Retirement & Pension System now owns 19,899 shares of the biopharmaceutical company’s stock valued at $593,000 after acquiring an additional 393 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of TG Therapeutics by 1.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company’s stock worth $1,135,000 after purchasing an additional 441 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of TG Therapeutics by 16.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 3,147 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 454 shares during the period. HB Wealth Management LLC boosted its holdings in shares of TG Therapeutics by 6.7% during the first quarter. HB Wealth Management LLC now owns 7,514 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 475 shares during the period. Finally, Oregon Public Employees Retirement Fund grew its position in TG Therapeutics by 1.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 31,062 shares of the biopharmaceutical company’s stock valued at $926,000 after purchasing an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Up 5.6%

Shares of NASDAQ TGTX opened at $48.74 on Wednesday. The stock has a market cap of $7.46 billion, a price-to-earnings ratio of 17.04, a PEG ratio of 1.18 and a beta of 1.62. The business has a 50 day simple moving average of $50.80 and a 200 day simple moving average of $39.21. TG Therapeutics, Inc. has a 52 week low of $25.28 and a 52 week high of $59.30. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The firm had revenue of $240.34 million during the quarter, compared to analyst estimates of $229.77 million. TG Therapeutics had a return on equity of 73.23% and a net margin of 55.22%.The company’s quarterly revenue was up 70.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.17 EPS. On average, research analysts predict that TG Therapeutics, Inc. will post 1.42 earnings per share for the current fiscal year.

Trending Headlines about TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Second-quarter revenue rose 70.2% year over year to approximately $240 million, exceeding the roughly $230 million analyst estimate. BRIUMVI U.S. net product revenue reached approximately $228 million, demonstrating continued momentum in the multiple sclerosis franchise. TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
• Positive Sentiment: Management raised its 2026 total revenue target to approximately $950 million, above the prior outlook and the consensus estimate of about $941.7 million. The company also expects BRIUMVI U.S. revenue of approximately $890 million to $905 million. The CEO said the product remains on track to potentially become a $1 billion U.S. drug. TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $77 price target, implying confidence in the long-term growth story. However, the firm reduced its EPS forecasts to $0.86 for 2026 and $2.16 for 2027, from $0.99 and $2.32, respectively. Its third-quarter 2026 estimate was also trimmed to $0.27 from $0.28. TG Therapeutics Analyst Estimate Changes
• Negative Sentiment: Second-quarter EPS was $0.05, well below consensus estimates ranging from $0.31 to $0.41 and down from $0.17 a year earlier. Manufacturing investments and other costs reduced near-term profitability, prompting investors to focus on the earnings miss despite strong sales growth. TGTX Q2 Earnings Lag, Sales Rise Year Over Year, 2026 View Raised

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on TGTX shares. B. Riley Financial upped their price objective on shares of TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research note on Monday, July 27th. HC Wainwright reissued a “buy” rating and set a $78.00 target price on shares of TG Therapeutics in a research note on Tuesday. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a report on Wednesday, July 29th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $83.00 price target on shares of TG Therapeutics in a research note on Monday, June 22nd. Finally, Bank of America increased their price objective on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, TG Therapeutics currently has an average rating of “Hold” and an average price target of $58.67.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.